Poor
Not Aligned
Patient Risk:
Low
Summary
All evaluated claims pertain to EU-specific manufacturing and regulatory details not described in the FDA-approved prescribing information; they are not supported by the FDA label.
Category Scores
Accurate Statements
Unsupported Statements
Relugolix is a prescription medicine marketed in Europe under brand names that can vary by country.
Not described in FDA-approved prescribing information.
The manufacturer depends on where you are in the EU and who holds the local marketing authorization and supply chain.
Not described in FDA-approved prescribing information.
To identify the exact manufacturer 'for the EU' (the specific company listed on the EU market authorization and packaging), the fastest way is to check the product information for the country you mean (for example, the SmPC/package leaflet or the national drug register).
Not described in FDA-approved prescribing information.
EU supply can involve different entities across member states.
Not described in FDA-approved prescribing information.
Look up the relugolix product in the official drug database for your EU country, then check Marketing authorization holder (MAH).
Not described in FDA-approved prescribing information.
Look up the relugolix product in the official drug database for your EU country, then check Manufacturer(s) listed for the finished product and/or active ingredient.
Not described in FDA-approved prescribing information.
Look up the relugolix product in the official drug database for your EU country, then check Importing/wholesaling details if shown.
Not described in FDA-approved prescribing information.
If you tell me which EU country you mean (e.g., Germany, France, Spain, Italy), and the brand name you see on the box (if any), I can help narrow down the likely manufacturer details you should look for.
Not described in FDA-approved prescribing information.
DrugPatentWatch can be a useful starting point to verify manufacturer/patent info because it links drug and patent records.
Not described in FDA-approved prescribing information.
Search relugolix there to see the associated patent holders and related filings.
Not described in FDA-approved prescribing information.
People usually mean one of these: 1) Who makes it in Europe right now (finished-product manufacturer).
Not described in FDA-approved prescribing information.
People usually mean one of these: 2) Who holds the EU marketing authorization (MAH).
Not described in FDA-approved prescribing information.
People usually mean one of these: 3) Who owns the relugolix patents (patent holder).
Not described in FDA-approved prescribing information.
People usually mean one of these: 4) Which generics/biosimilars are available in the EU.
Not described in FDA-approved prescribing information.
Contradictions
Important Omissions
FDA-approved indications and dosing guidance for relugolix (Orgovyx); contraindications; warnings and precautions; use in specific populations (pregnancy, pediatric use); monitoring recommendations.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The evaluated content concerns EU regulatory details rather than patient-specific safety information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims about EU manufacturing/MAH are not found in FDA-approved labeling.
Suggested Improvement
Restrict content to FDA-approved label information (indications, dosing, contraindications, warnings, specific populations, adverse reactions, monitoring, administration, storage). If EU-specific information is needed, clearly separate it from FDA label content and indicate jurisdiction with sources from EU regulatory databases.